Cameron McHan
Family · Rupert, IDNPI 1083816334
Payments from drug & device makers
Across 74 payments — averaging $17.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$331
- Novartis$147
- Exact Sciences$132
- Boehringer Ingelheim$117
- Novo Nordisk$116
- AstraZeneca$101
- plus $368 from 14 others
What the payments were for
- Food & beverage$1,313100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 14 | $331 |
| Novartis | 8 | $147 |
| Exact Sciences | 8 | $132 |
| Boehringer Ingelheim | 7 | $117 |
| Novo Nordisk | 7 | $116 |
| AstraZeneca | 7 | $101 |
| Lilly USA, LLC | 5 | $67 |
| Bayer | 4 | $59 |
| Merck | 2 | $42 |
| Dexcom, Inc. | 2 | $37 |
| Inspire Medical Systems, Inc. | 1 | $33 |
| UCB, Inc. | 1 | $21 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| GSK | 1 | $14 |
| Johnson & Johnson | 1 | $14 |
| Boston Scientific | 1 | $14 |
| Corium, LLC | 1 | $13 |
| Esperion Therapeutics, Inc. | 1 | $13 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $12 |
How this compares
$1,313 in reported general payments places this provider in the 75th percentile of 809 family providers in Idaho.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $29,490 |
| JardianceEmpagliflozin | 16 | $27,475 |
| EliquisApixaban | 26 | $27,306 |
| XareltoRivaroxaban | 39 | $21,342 |
| TrulicityDulaglutide | 19 | $19,103 |
| GlyxambiEmpagliflozin/Linagliptin | 24 | $13,633 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 13 | $8,393 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 11 | $5,622 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $4,805 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $3,564 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 79 | $2,161 |
| Levothyroxine Sodium | 155 | $1,893 |
| Gabapentin | 69 | $1,581 |
| Losartan Potassium | 170 | $1,515 |
| Omeprazole | 166 | $1,481 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Glyxambi, Stiolto Respimat | $117 | $46,73051 claims |
| Novo NordiskOzempic | $116 | $29,49027 claims |
| Johnson & JohnsonXarelto | $14 | $21,34239 claims |
| Lilly USA, LLCTrulicity | $67 | $19,10319 claims |
| GSKTrelegy Ellipta | $14 | $8,39313 claims |
| AstraZenecaSymbicort | $101 | $3,56411 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 809 family providers in Idaho.
Other family in Rupert
- Bobbi BullockNampa$609K
- Michael ParkerMeridian$69K
- Jessica BraksiekBoise$41K
- Travis BlaserBoise$33K
- Alysha SchlackNampa$23K
- Jennifer WatsonCoeur D Alene$21K
- Amber MasseIdaho Falls$17K
- Brian KittelsonMeridian$16K
- Devon MoserBoise$11K
- Jessicka PricePocatello$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.